Pharmaceutical - Markets & Marketing, Benlysta

Filter

Popular Filters

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

25-10-2012

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

COMPANY SPOTLIGHT

Menarini

Back to top